CompletedNCT00644800
A Study of the Efficacy and Safety of Intramuscular Ziprasidone Followed by Oral Ziprasidone for the Treatment of Psychosis
Medication studyAges 18–55BrazilSchizophrenia
Understand this study
Who was this study for?
Listed age limits: 18 years to 55 years.
- Listed locations
- Fortaleza and 7 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateJuly 2003
- Recruitment status
- Completed
- Enrollment listed in the registry
- 89
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Brazil
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT00644800
- Official title
Show the full official title
An Open, Multicenter, Non-Comparative Study To Assess The Efficacy And Tolerability Of Intramuscular Ziprasidone Followed By Oral Ziprasidone In Patients With Acute Psychosis
Get this study by email
Recruitment & locations
CompletedFortaleza · Salvador · Belo Horizonte
5 more locations
- Curitiba
- Rio de Janeiro
- São Gonçalo
- Jardim Santa Monica SN
- São Paulo
Questions about this study
Who is behind this study?
The study sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Did this study involve medication?
Yes. The study involved medication, including Ziprasidone.
Who was this study for?
Listed age limits: 18 years to 55 years.
